Frank P. Zemlan
Directeur Général chez Phase 2 Discovery, Inc.
Postes actifs de Frank P. Zemlan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Phase 2 Discovery, Inc.
 Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Directeur Général | - | - |
Historique de carrière de Frank P. Zemlan
Anciens postes connus de Frank P. Zemlan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| GSK PLC | Corporate Officer/Principal | - | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Formation de Frank P. Zemlan
| Villanova University | Graduate Degree |
| University of Pennsylvania | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Royaume-Uni | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 2 |
|---|---|
Phase 2 Discovery, Inc.
Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH. | Health Technology |
| Aventis, Inc. |
- Bourse
- Insiders
- Frank P. Zemlan
- Expérience
